Predictive value of antibodies to citrullinated peptides and rheumatoid factors in anti-TNF-alpha treated patients.
Ann N Y Acad Sci
; 1109: 287-95, 2007 Aug.
Article
em En
| MEDLINE
| ID: mdl-17785317
ABSTRACT
This article will focus on the relationship between serum levels of anti-citrullinated peptide antibodies (anti-CCP) or rheumatoid factor (RF) and clinical response to TNF-alpha blockers in order to evaluate whether these antibodies may have a role as serological markers of response to therapy in rheumatoid arthritis (RA). The changes induced in anti-CCP levels after TNF blocking therapy still remain a controversial issue even though a marked reduction following conventional DMARDs has been reported in early disease. On the other hand, a drop in RF levels during treatment has been reported by many authors. Decreased IgM RF levels seem to parallel clinical response suggesting that this antibody can also be regarded as a marker of response to treatment. Pre-treatment RF positivity or negativity does not influence response to TNF-alpha blocking therapy while high pre-treatment levels of IgA RF seem to be associated with a poor response rate.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Peptídeos
/
Artrite Reumatoide
/
Autoanticorpos
/
Fator de Necrose Tumoral alfa
Tipo de estudo:
Prognostic_studies
/
Risk_factors_studies
Limite:
Humans
Idioma:
En
Ano de publicação:
2007
Tipo de documento:
Article